CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Targeting the fusion oncoprotein BCR-ABL with tyrosine kinase inhibitors has significantly affected chronic myeloid leukemia (CML) treatment, transforming the life expectancy of patients; however the risk for relapse remains, due to persistence of leukemic stem cells (LSCs). Therefore it is imperati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Tarafdar, Anuradha, Hopcroft, Lisa E. M., Gallipoli, Paolo, Pellicano, Francesca, Cassels, Jennifer, Hair, Alan, Korfi, Koorosh, Jørgensen, Heather G., Vetrie, David, Holyoake, Tessa L., Michie, Alison M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5305055/
https://ncbi.nlm.nih.gov/pubmed/27793879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-742049
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars